US 11,891,415 B2
Depsipeptides and uses thereof
Dallas Hughes, Bolton, MA (US); Amy Spoering, Waltham, MA (US); Aaron J. Peoples, Somerville, MA (US); Losee Lucy Ling, Arlington, MA (US); Anthony Nitti, Lexington, MA (US); William Millett, Worcester, MA (US); Ashley Zullo, Cambridge, MA (US); Kim Lewis, Newton, MA (US); Slava Epstein, Dedham, MA (US); Alysha Desrosiers, Medford, MA (US); Catherine Achorn, Cambridge, MA (US); and Kelly Demeo, Brookline, MA (US)
Assigned to NovoBiotic Pharmaceuticals, LLC, Cambridge, MA (US)
Filed by NovoBiotic Pharmaceuticals, LLC, Cambridge, MA (US)
Filed on Nov. 11, 2021, as Appl. No. 17/524,230.
Application 17/524,230 is a continuation of application No. 16/500,470, granted, now 11,203,616, previously published as PCT/US2018/025365, filed on Mar. 30, 2018.
Claims priority of provisional application 62/481,412, filed on Apr. 4, 2017.
Prior Publication US 2022/0185845 A1, Jun. 16, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 11/02 (2006.01); A61P 31/04 (2006.01); C12N 1/20 (2006.01); A61K 38/00 (2006.01)
CPC C07K 11/02 (2013.01) [A61P 31/04 (2018.01); C12N 1/20 (2013.01); A61K 38/00 (2013.01)] 20 Claims
 
1. A compound of the following structural formula:

OG Complex Work Unit Chemistry
or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.